Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Of Spil's Estradiol Vaginal Tablet

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal woman~* At least one subject-self-assessed moderate to severe symptom of vulvar and vaginal atrophy~* ≤ 5% superficial cells on vaginal smear cytology~* Vaginal pH \> 5.0~Exclusion Criteria:~* Consumption of estrogen alone or estrogen/progestin containing drug products.~* Allergy to estradiol or related products~* History of breast cancer and significant risk factors for endometrial cancer~* Abnormal genital bleeding

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Estradiol (Type: EXPERIMENTAL): Intravaginal self-administration of study medication once daily for 14 days.
- Reference: Estradiol (Type: ACTIVE_COMPARATOR): Intravaginal self-administration of study medication once daily for 14 days.
- Placebo (Type: PLACEBO_COMPARATOR): Intravaginal self-administration of study medication once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).